Morphogenesis Awarded SBIR Funding for Cervical Cancer Therapy (Morphogenesis)

Morphogenesis Awarded SBIR Funding for Cervical Cancer Therapy

UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a clinical-stage biotechnology company, has obtained funding to develop a new therapeutic drug to treat cervical cancer. Globally, more than half a million women are diagnosed and over 300,000 die from cervical cancer each year due to lack of access to lifesaving care. Cancer treatment regimens in low-resource settings require a fundamental transformation to overcome this horrific toll.

A multi-discipline team that includes scientists from Morphogenesis, Medisca, a pharmaceutical compounding company specializing in customized medication, and Moffitt Cancer Center, is developing an innovative therapy that would expand care to patients with limited access to lifesaving treatments. A Small Business Innovation Research (SBIR) proposal entitled, “A low-cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle-income countries and low-resource settings in the U.S.”, received excellent scores following a competitive review process, and was awarded US$400,000 from the National Cancer Institute (NCI) at the National Institutes of Health (NIH). The proposed work will reformulate Morphogenesis’s immunomodulatory cancer drug, IFx-Hu2.0, to a preparation that is applicable to treat women in locations with limited healthcare infrastructure.

Learn more about Morphogenesis Awarded SBIR Funding for Cervical Cancer Therapy.